---
title: "Parmax Pharma Ltd (540359) — Share Price, Financials & Analysis"
symbol: "540359"
company: "Parmax Pharma Ltd"
canonical: "https://tapetide.com/stocks/540359"
isin: "INE240T01014"
nse_symbol: "PARMAXPHARMALTD"
bse_code: "540359"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 91.1
generated_at: "2026-09-13T18:58:18.260Z"
---

# Parmax Pharma Ltd (540359)

Canonical page: https://tapetide.com/stocks/540359

## Company

- **NSE Symbol:** PARMAXPHARMALTD
- **BSE Code:** 540359
- **ISIN:** INE240T01014
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2017-03-17
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** parmaxpharma.com

## About

Incorporated in 1994, Parmax Pharma Ltd manufactures Bulk Drugs, Drug Intermediates & Speciality Chemicals.[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-07T04:34:15.896322Z.

- **Market Cap:** ₹91.1 Cr
- **Classification:** Microcap
- **P/E (reported):** -76.1
- **EPS (TTM):** ₹-3.18
- **Book Value:** ₹6.68
- **Price to Book:** 19.83
- **Dividend Yield:** 0%
- **ROE:** 105.3%
- **ROCE:** -31.66%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹12.11 Cr
- **Net Income:** ₹-5.85 Cr
- **EBITDA:** ₹-3.64 Cr
- **52-Week High:** ₹132.45
- **52-Week Low:** ₹22.6

## Tapetide Score

- **Score:** 40 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 14.5 (of 4473 scored stocks)
- **Confidence:** 84%
- **Data coverage:** 67%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 13.16 | 9% |
| growth | 16.7 | 9% |
| momentum | 98.9 | 12% |
| ownership | 50 | 24% |
| quality | 16.34 | 22% |
| valuation | 39.48 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter
- Promoter holding has increased by 33.9% over last quarter.

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -14.3% over past five years.
- Debtor days have increased from 57.4 to 95.2 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -380% | -390.91% | -127.2% |
| ebitda margin growth | 293.33% | — | 0% | -309.15% |
| net income growth | 466.67% | 178.57% | 0.86% | — |
| revenue growth | 212.12% | -57.06% | -8% | -14% |
| roce | — | -61.52% | -899.49% | -17.98% |
| roe | — | -101.93% | — | 711.87% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 4.07 | 1.33 | 4.26 | 7.82 | 9.28 | 6.28 | 4.83 | 1.94 | 2.53 | 4.33 | 3.31 | 8.22 |
| Expenses | 4.84 | 2.48 | 5.06 | 7.31 | 9.08 | 6.17 | 5.39 | 2.19 | 4.12 | 4.53 | 4.86 | 7.39 |
| Operating Profit | -0.77 | -1.15 | -0.8 | 0.51 | 0.2 | 0.11 | -0.56 | -0.25 | -1.59 | -0.2 | -1.55 | 0.83 |
| OPM % | -18.92 | -86.47 | -18.78 | 6.52 | 2.16 | 1.75 | -11.59 | -12.89 | -62.85 | -4.62 | -46.83 | 10.1 |
| Other Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.12 | 0.01 | -1.17 | 0.01 | 0.01 | 0.01 | 0.03 | 2.08 |
| Interest | 0.18 | 0.16 | 0.16 | 0.11 | 0.13 | 0.11 | 0.24 | 0.28 | 0.24 | 0.28 | 0.5 | 0.23 |
| Depreciation | 0.43 | 0.45 | 0.41 | 0.4 | 0.4 | 0.41 | -0.18 | 0.24 | 0.26 | 0.27 | 0.25 | 0.48 |
| Profit before tax | -1.37 | -1.75 | -1.36 | 0.01 | -0.21 | -0.4 | -1.79 | -0.76 | -2.08 | -0.74 | -2.27 | 2.2 |
| Tax % | 0 | 0 | 6.62 | 0 | 0 | 0 | -16.76 | 0 | 0 | 0 | -74.45 | 0 |
| Net Profit | -1.37 | -1.75 | -1.45 | 0.01 | -0.22 | -0.39 | -1.49 | -0.76 | -2.08 | -0.73 | -0.58 | 2.2 |
| EPS in Rs | -3.66 | -4.68 | -3.88 | 0.03 | -0.59 | -1.04 | -3.98 | -2.03 | -5.56 | -1.95 | -1.55 | 5.88 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 11.89 | 11.99 | 20.92 | 26.17 | 18.24 | 15.39 | 11.02 | 28.2 | 12.11 | 18.39 |
| Expenses | 10.81 | 10.88 | 19.15 | 22.74 | 15.67 | 13.14 | 14.39 | 27.94 | 15.75 | 20.9 |
| Operating Profit | 1.08 | 1.11 | 1.77 | 3.43 | 2.57 | 2.25 | -3.37 | 0.26 | -3.64 | -2.51 |
| OPM % | 9.08 | 9.26 | 8.46 | 13.11 | 14.09 | 14.62 | -30.58 | 0.92 | -30.06 | -13.65 |
| Other Income | 0.05 | 0.05 | 0.1 | 0.09 | 0.06 | 0.04 | 0.05 | -1.03 | 0.05 | 2.13 |
| Interest | 0.04 | 0.03 | 0.13 | 0.37 | 0.39 | 0.37 | 0.62 | 0.59 | 1.24 | 1.25 |
| Depreciation | 1.09 | 1.03 | 1.01 | 1.94 | 1.93 | 1.88 | 1.71 | 1.03 | 1.01 | 1.26 |
| Profit before tax | 0 | 0.1 | 0.73 | 1.21 | 0.31 | 0.04 | -5.65 | -2.39 | -5.84 | -2.89 |
| Tax % | — | 20 | 41.1 | 38.02 | 54.84 | 375 | 1.77 | -12.55 | -28.94 | — |
| Net Profit | 0 | 0.08 | 0.43 | 0.75 | 0.14 | -0.1 | -5.75 | -2.09 | -4.16 | -1.19 |
| EPS in Rs | 0 | 0.21 | 1.15 | 2 | 0.37 | -0.27 | -15.37 | -5.59 | -11.12 | -3.18 |
| Dividend Payout % | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 | 4.45 |
| Reserves | 0.1 | 0.11 | 0.18 | 0.61 | 1.37 | 1.51 | 1.4 | -4.35 | -6.44 | -10.6 |
| Borrowings | 1.02 | 1.96 | 5.52 | 5.26 | 5.89 | 5.18 | 5.37 | 5.91 | 7.71 | 11.52 |
| Other Liabilities | 2.14 | 10.11 | 9.56 | 10.75 | 11.01 | 6.83 | 6.39 | 9.32 | 13.03 | 22.68 |
| Total Liabilities | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 28.05 |
| Fixed Assets | 2.72 | 5.86 | 4.92 | 9.64 | 10.84 | 10.44 | 9.5 | 9.27 | 7.97 | 7.86 |
| CWIP | 0 | 0 | 3.33 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0 |
| Investments | 0 | 0 | 0.2 | 0.2 | 0.2 | 0 | 0 | 0 | 0.4 | 0.4 |
| Other Assets | 4.99 | 10.77 | 11.26 | 11.23 | 11.68 | 7.53 | 8.11 | 5.96 | 10.38 | 19.79 |
| Total Assets | 7.71 | 16.63 | 19.71 | 21.07 | 22.72 | 17.97 | 17.61 | 15.33 | 18.75 | 28.05 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -0.5 | 3.88 | 0.92 | 2.82 | 3.53 | 0.75 | 0.33 | -0.2 | -0.96 | -2.36 |
| Cash from Investing Activity | -0.19 | -4.23 | -3.41 | -2.4 | -3.15 | -1.53 | -0.94 | -1.59 | -0.7 | -0.9 |
| Cash from Financing Activity | 0.56 | 1.14 | 3.1 | -0.23 | 0.4 | -0.91 | -0.04 | 1.43 | 1.4 | 3.81 |
| Net Cash Flow | -0.14 | 0.79 | 0.61 | 0.2 | 0.78 | -1.69 | -0.65 | -0.36 | -0.26 | 0.56 |
| Free Cash Flow | -0.69 | -0.35 | -2.49 | 0.42 | 0.38 | -0.78 | -0.61 | -1.79 | -1.66 | -3.26 |
| CFO/OP | 1000 | 359 | 83 | 159 | 103 | 29 | 15 | 6 | -369 | 65 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | — | 60.48 | 35.01 | 57.58 | 23.01 | 13.61 | 14.7 | 60.28 | 16.57 | 95.24 |
| Inventory Days | — | 203.34 | 278.66 | 88.17 | 107.27 | 154.8 | 286.55 | 123.74 | 56.09 | 290.01 |
| Days Payable | — | 609.39 | 645.07 | 311.84 | 269.4 | 299.82 | 309.82 | 382.6 | 173.18 | 529.77 |
| Cash Conversion Cycle | — | -345.57 | -331.4 | -166.09 | -139.12 | -131.41 | -8.57 | -198.58 | -100.52 | -144.52 |
| Working Capital Days | — | -59.86 | -71.84 | -56.18 | -48.26 | -36.02 | -0.47 | -115.59 | -40.38 | -200.43 |
| ROCE % | 0.19 | 0.66 | 1.56 | 8.4 | 14.34 | 6.13 | 3.67 | -58.39 | -12.45 | -82.96 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 30.8% | 30.8% | 30.83% | 30.8% | 30.8% | 30.8% | 30.8% | 30.8% | 30.8% | 30.8% | 30.8% | 30.8% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 65.43% | 65.43% | 65.34% | 65.78% | 62.9% | 63.12% | 63.1% | 63.1% | 63.09% | 63.08% | 63.1% | 56.25% |
| Others | 3.76% | 3.77% | 3.83% | 3.42% | 6.29% | 6.08% | 6.1% | 6.1% | 6.11% | 6.12% | 6.09% | 12.95% |
| No. of Shareholders | 1973 | 2002 | 2099 | 2185 | 2246 | 2334 | 2356 | 2377 | 2399 | 2393 | 2388 | 2273 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 1 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 125.54 | Buy |
| EMA (10) | 125.85 | Buy |
| SMA (20) | 115.88 | Buy |
| EMA (20) | 118.34 | Buy |
| SMA (50) | 99.61 | Buy |
| EMA (50) | 99.88 | Buy |
| SMA (100) | 68.31 | Buy |
| EMA (100) | 79.61 | Buy |
| SMA (200) | 50.29 | Buy |
| EMA (200) | 62.06 | Buy |

### Oscillators — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 88.59 | Sell |
| MACD (12,26,9) | 9.84 | Buy |
| Stochastic (14,3,3) | 100 | Sell |
| ADX (14) | 63.34 | Buy |
| Williams %R (14) | 0 | Sell |
| ATR (14) | 2.17 | Neutral |
| ROC (12) | 22.88 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 96.35 | Sell |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a76faff-2b95-4932-8a5a-00129c35b6bd.pdf) |
| 2026-09-07 | [Notice Of Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8b2fb80-660e-406b-8c3b-afc96e1fd74b.pdf) |
| 2026-09-07 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3e9f1413-a91a-4dd7-b918-bf511779cd28.pdf) |
| 2026-09-02 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=191E8B06_1571_4FFC_A33F_079D5A3C6C00_104657.pdf) |
| 2026-08-29 | [Announcement under Regulation 30 (LODR)-Allotment](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea1bf6e6-1776-493c-a990-b5048adc6410.pdf) |
| 2026-08-24 | [Post Offer Advertisement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=E5E471CC-AEAE-4571-AC0B-3DE7E37F029A-140516.pdf) |
| 2026-08-24 | [Intimation Of Reclassification Of Promoters Under Regulation 31A Of SEBI (LODR) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c0bec1e-e495-4008-af8a-e5249a4bcbb6.pdf) |
| 2026-08-22 | [Receipt Of In-Principle Approval Under Regulation 28(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For Issuance Of Equity Shares And Warrants On Preferential Basis](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2e3ffc2-4d93-4f17-94f9-7aa9f929b834.pdf) |
| 2026-08-17 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5333DD26_DC54_4E69_B3C3_EF70AD0C0C06_142500.pdf) |
| 2026-08-17 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47C15302_DFF1_4371_A788_3396D55CA0E5_150531.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Results For Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aee79244-6f3c-4451-99cf-a7260d3f9ba7.pdf) |
| 2026-06-03 | [Results-Delay in Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1cbdc9ab-3474-4731-8d0e-9608cf74690d.pdf) |
| 2026-02-14 | [Unaudited Financial Results For Quarter And Nine Months Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27bda5c5-8cce-402a-91ce-0659b327faeb.pdf) |
| 2025-11-17 | [Results-Delay in Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1bc7c481-3586-4a77-8429-deee332f92bc.pdf) |
| 2025-08-14 | [Unaudited Financial Results For Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2885a44-b5bb-4cc3-b584-b0cbbcbb2154.pdf) |
| 2025-08-14 | [Financial Statements For Quarter Ended 30Th June 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=062af9a4-e102-49b5-86b9-328483187eff.pdf) |
| 2025-05-30 | [FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31/03/2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b8afe27d-b588-4a26-84ff-8305fa2dbdda.pdf) |
| 2025-02-14 | [Financial Results For The Quarter Ended On 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c93bdc9d-b142-401f-a14d-dacfb252b8c3.pdf) |
| 2024-11-15 | [Financial Results For The Quarter And Half Year Ended On 30Th September, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ac4fa1c-6d54-4b40-8ab5-23074501f446.pdf) |
| 2024-08-14 | [Financial Results For Quarter Ended On 30/06/2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0185fd32-b23b-42b0-b52f-fac8502570ed.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Board meeting Feb 14, 2026 to approve unaudited results for quarter/9 months ended Dec 31, 2025. | [Board Meeting Intimation for Consider And Approve Unaudited Financial Results For Quarter And Nine Months Ended On December 31, 2025 9 Feb - Board meeting Feb 14, 2026 to approve unaudited results for quarter/9 months ended Dec 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/20ef4111-7558-4fb1-9df6-6af3cacb8cc4.pdf) |
| 30 Mar - Trading window closed Apr 1, 2026 until 48 hours after results for quarter/year ending Mar 31, 2026. | [Closure of Trading Window 30 Mar - Trading window closed Apr 1, 2026 until 48 hours after results for quarter/year ending Mar 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/929bc83f-a565-4b4a-ac17-362e59af6778.pdf) |
| 30 Dec 2025 - Trading window closed Jan 1, 2026 until 48 hours after Dec 31, 2025 quarter results; board date to be intimated. | [Closure of Trading Window 30 Dec 2025 - Trading window closed Jan 1, 2026 until 48 hours after Dec 31, 2025 quarter results; board date to be intimated.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d748dd4f-c85a-4acb-934a-12d4d12bed4a.pdf) |
| 30 Apr - Parmax Pharma confirms it is not a Large Corporate under SEBI circulars. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Parmax Pharma confirms it is not a Large Corporate under SEBI circulars.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/36a9639a-4036-4658-b5a5-19930bda0d57.pdf) |
| 30 Apr - Parmax Pharma confirms it is not a Large Corporate under SEBI circulars. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 30 Apr - Parmax Pharma confirms it is not a Large Corporate under SEBI circulars.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/36a9639a-4036-4658-b5a5-19930bda0d57.pdf) |
| 25 Mar - Ms. Bhakti Aghera appointed Company Secretary & Compliance Officer, effective March 24, 2026. | [Appointment of Company Secretary and Compliance Officer 25 Mar - Ms. Bhakti Aghera appointed Company Secretary & Compliance Officer, effective March 24, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dca3fdff-4a08-4715-8b3b-1bf462c517fc.pdf) |
| 2 May - Board reappointed Dr. Umang Gosalia as Managing Director for five years from June 28, 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 2 May - Board reappointed Dr. Umang Gosalia as Managing Director for five years from June 28, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5b71a90b-2747-47a7-97eb-160c39d6ca92.pdf) |
| 2 May - Board reappointed Dr. Umang Gosalia as Managing Director for five years from June 28, 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 2 May - Board reappointed Dr. Umang Gosalia as Managing Director for five years from June 28, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/5b71a90b-2747-47a7-97eb-160c39d6ca92.pdf) |
| 17 Apr - Regulation 74(5) certificate for quarter ended March 31, 2026; two share certificates dematerialized. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 17 Apr - Regulation 74(5) certificate for quarter ended March 31, 2026; two share certificates dematerialized.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0e384c39-0705-4e74-8bdb-d688291b94b5.pdf) |
| 14 Feb - Unaudited Q3/9M results to Dec 31, 2025: 9M loss Rs35,747.61k; revenue Rs87,988.87k; audit unqualified. | [Unaudited Financial Results For Quarter And Nine Months Ended 31.12.2025 14 Feb - Unaudited Q3/9M results to Dec 31, 2025: 9M loss Rs35,747.61k; revenue Rs87,988.87k; audit unqualified.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/27bda5c5-8cce-402a-91ce-0659b327faeb.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d46b07e5-09ad-4a79-b8ca-5a30303019da.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1bdb987e-b8df-4821-9756-1b053d7ac13d.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1d9d5222-725e-4c66-add6-fd1c371ac19d.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/540359/76922540359_23_09_22.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/540359/70116540359_21_09_21.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/540359/67235540359.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/540359/5403590319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/540359/5403590318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/540359/5403590317.pdf) |
| from bse | [Annual Report 2016 from bse](https://www.bseindia.com/HIS_ANN_RPT/HISTANNR/2016/PARMAX_PHARMA_LTD-540359-MARCH-2016.PDF) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:58:18.260Z.